Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

Nona Biosciences’ proprietary Harbour Mice ® platform generates monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. The HCAb Harbour Mice ® platform is ...

The "Birds of a Feather" singer is nominated seven times. Billie Eilish has made her much-anticipated, grand arrival to the 2025 Grammy Awards. And while fans will have to wait and see if she wins ...

We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a condition of the nervous system that can be managed with lifestyle modifications or medications, depending on your individual needs.

Lebrikizumab, a monoclonal antibody that inhibits interleukin-13, is one such biologic that has shown long-term efficacy in this population group as demonstrated in the phase 3 clinical trial ...